MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives $35.00 Average Target Price from Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have been assigned a consensus rating of “Hold” from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $35.00.

INKT has been the subject of several analyst reports. Zacks Research raised MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 20th. Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th.

MiNK Therapeutics Stock Up 0.7%

MiNK Therapeutics stock opened at $12.36 on Tuesday. The company’s 50-day moving average price is $11.75 and its 200-day moving average price is $14.30. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $76.00. The company has a market cap of $57.97 million, a PE ratio of -4.08 and a beta of 0.34.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.21. As a group, sell-side analysts expect that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.